Castle Rock Wealth Management LLC Sells 1,116 Shares of Amgen Inc. (NASDAQ:AMGN)

Castle Rock Wealth Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 16.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,777 shares of the medical research company's stock after selling 1,116 shares during the quarter. Castle Rock Wealth Management LLC's holdings in Amgen were worth $1,783,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at approximately $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen in the 4th quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE increased its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new position in Amgen during the 4th quarter worth approximately $34,000. Finally, Atala Financial Inc acquired a new position in Amgen during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on AMGN. Mizuho boosted their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Piper Sandler cut their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. Finally, Royal Bank of Canada cut their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $309.22.

Amgen Trading Up 1.3%

Amgen stock traded up $3.63 during trading hours on Thursday, reaching $290.64. The stock had a trading volume of 668,867 shares, compared to its average volume of 2,798,412. The stock has a market cap of $156.28 billion, a PE ratio of 38.50, a PEG ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a fifty day simple moving average of $282.39 and a 200-day simple moving average of $285.31.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same period in the previous year, the company earned $3.96 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.